Escalating to medium‐ versus high‐efficacy disease modifying ...

Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis.

Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.

versus high-efficacy disease modifying therapy after low ... - PubMed

Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis ... Brain Behav. 2024 ...

(PDF) Escalating to medium‐ versus high‐efficacy disease ...

Escalation to high‐efficacy DMTs was associated with lower hazards of relapses than medium‐efficacy DMTs (HR = 0.67, 95% CI 0.47–0.95, p = .027) ...

Escalation Versus Induction/High-Efficacy Treatment Strategies for ...

The disease-modifying drugs (DMDs) that are currently available are not effective once conversion has occurred, for by that stage, acute focal ...

How do you decide between escalation to a high efficacy DMT

... disease-modifying therapies for multiple sclerosis? How do you distinguish between primary progressive MS versus relapsing remitting MS with superimposed ...

Evaluating the Effect of Disease Duration in High Efficacy Versus ...

Evaluating the Effect of Disease Duration in High Efficacy Versus Mid Efficacy Disease Modifying Therapies: Could This Help in Deciding When to De-escalate?

De-Escalation from High- or Moderate-Efficacy ... - Practical Neurology

KEYWORDS: · CMSC 2023 · Multiple sclerosis · Disease Modifying Therapy · Dimethyl fumarate · Fingolimod · Glatiramer acetate · interferons ...

Escalation or high-efficacy disease-modifying therapies in multiple ...

Escalating treatment means starting with the safest disease-modifying therapies with moderate effect. High-efficacy therapies mean starting with ...

Escalation vs Early Aggressive Treatment in Multiple Sclerosis

... moderate-efficacy disease-modifying therapy (DMT) to a higher-efficacy DMT when breakthrough disease activity occurs. In this article, Yinan Zhang, MD ...

Escalation or high-efficacy disease-modifying therapies in multiple ...

Escalating treatment means starting with the safest disease-modifying therapies with moderate effect. High-efficacy therapies mean starting with a strong ...

Initial high-efficacy disease-modifying therapy in multiple sclerosis

This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.

Treatment Escalation vs Immediate Initiation of Highly Effective ...

Meaning This study suggests that escalation of treatment was inferior to using a more effective disease-modifying treatment as initial treatment ...

Benefits of early highly effective versus escalation treatment ...

In an EHT strategy, pwMS start with CLA, OCR, OFA or NAT in line 1, followed by other high-efficacy DMTs (NAT, CLA, OCR, OFA and ALE) in lines 2 ...

Does initial high efficacy therapy in multiple sclerosis surpass ...

In relapsing-remitting multiple sclerosis (RRMS) the most common treatment strategy has been to start with low-moderate efficacy disease modifying therapy (LE- ...

versus high-efficacy disease modifying therapy after low ... - EBSCO

Title. Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis. Authors ...

Does initial high efficacy therapy in multiple sclerosis surpass ...

... moderate efficacy disease modifying therapy (LE-DMT) and to escalate to more efficacious treatments in cases of breakthrough disease activity. However ...

Early intensive MS treatment versus escalation approach

... or dimethyl fumarate, escalating to high-efficacy disease modifying treatments (DMTs) upon treatment failure. Evidence from randomized ...

Evolution of Disease Modifying Therapy Benefits and Risks - Frontiers

Background: Strategies for sequencing disease modifying therapies (DMTs) in multiple sclerosis (MS) patients include escalation, high efficacy early, induction, ...

De-escalation of Disease-Modifying Therapy for People with ...

One study reported that 40% of older people with progressive MS still progressed on anti-CD20 therapy (60% remained stable or improved) after 2 ...